# David J. Mangelsdorf

> David J. Mangelsdorf is a startup investor at Ligand Pharmaceuticals. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ligand Pharmaceuticals](https://shizune.co/investors/profile/ligand-pharmaceuticals)
- Last updated: Aug 2026

David J. Mangelsdorf is a startup investor at Ligand Pharmaceuticals. David J. Mangelsdorf, PhD, has been Professor and Chair of the Department of Pharmacology at the University of Texas Southwestern Medical Center at Dallas since 1993. He holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science. His research is focused on the mechanism of action of nuclear receptors and the characterization oftheir ligand activities. His work has led to the therapeutic targeting of nuclear receptors for diseases such as atherosclerosis, cholestasis, type 2 diabetes, and cancer. He has been involved in the start-up of several biotech companies, including Ligand Pharmaceuticals and X-Ceptor Therapeutics. He completed postdoctoral studies at the Salk Institute for Biological Sciences after receiving a PhD in biochemistry from the University of Arizona in Tucson. He is a member of the National Academy of Sciences and an Investigator of the Howard Hughes Medical Institute.

## About Ligand Pharmaceuticals

VC Fund · San Diego, United States

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporatecost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

5 contacts available at Ligand Pharmaceuticals.

| Name | Title | Profile |
| --- | --- | --- |
| Bob Chen | Director, Systems Engineering and Site Head | https://shizune.co/investors/profile/bob-chen-4a5d |
| David J. Mangelsdorf | Team Member | https://shizune.co/investors/profile/david-j-mangelsdorf |
| John Higgins | CEO | https://shizune.co/investors/profile/john-l-higgins |
| Richard Baxter | Senior Vice President of Investment Operations | https://shizune.co/investors/profile/richard-baxter-8ec4 |
| Todd C. Davis | Chief Executive Officer & Director | https://shizune.co/investors/profile/todd-c-davis |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co